BVIF-backed ViraTherapeutics appoints CEO
ViraTherapeutics, a biopharmaceutical company developing virus-based immunotherapeutics, which is backed by Boehringer Ingelheim Venture Fund (BIVF), has appointed Dr Heinz Schwer as CEO. He takes over the position from interim CEO and co-founder Professor Dr Dorothee von Laer, who will remain a scientific adviser. Schwer is a biotech